Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Feature

The mGlu5 receptor: a target for antagonists with improved anxiolytic activity

Posted on: 13 Jul 05

Summary

Anxiety disorders affect 20% of the total population across the seven major markets. Recent data demonstrates the efficacy of MPEP, the prototypical mGlu5 receptor antagonist as a an anxiolytic. Efficacy was similar compared to that of diazepam but at anxiolytic doses produces less cognitive decline
Anxiety disorders affect 20% of the total population across the seven major markets (see our feature Anxiety Disorders - More Than Just a Comorbidity) and are commonly treated with antidepressants.  Adverse effects lead to treatment discontinuation in as many as 16% of patients driving the drug development sector to identify alternative approaches to anxiety.  Benzodiazepines are treated cautiously by many physicians for reasons of dependency and withdrawal problems, as well as adverse effects including cognitive impairment.  Glutamate (mGlu5) receptor antagonists are being developed as an improved class of anxiolytics and here we highlight the efficacy of MPEP, the prototypical mGlu5 receptor antagonist, which was similar compared to that of diazepam but at anxiolytic doses produces less cognitive decline...[more]

Featured on DailyUpdates-CNS Disorders

LeadDiscovery

Last updated on: 27/08/2010 11:40:18

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.